Table 2. Clinical outcomes of the study patients.a.
| Outcome/adverse effect | TGC group (n = 30) | CST group (n = 40) | P |
|---|---|---|---|
| Clinical success | 14 (47) | 19 (48) | 0.95 |
| Recurrence of infection | 2 (7) | 4 (10) | 0.69 |
| Microbiological success | 7 (23) | 12 (30) | 0.54 |
| Day 7 CPIS | 6.0 (4.0–7.0) | 5.5 (4.0–7.0) | 0.97 |
| Δ CPIS b | -1.0 (-2.0–1.0) | -1.0 (-3.0–1.0) | 0.46 |
| Day 7 radiologic score | 5.0 (2.0–7.0) | 5.0 (3.5–7.5) | 0.85 |
| Δ radiologic score b | -1.0 (-2.0–0) | 0 (-1.5–1.0) | 0.43 |
| MV after pneumonia c, days | 10 (5–28) | 11 (6–33) | 0.71 |
| ICU stay after pneumonia c, days | 15 (7–28) | 13 (9–39) | 0.96 |
| Hospital stay after pneumonia c, days | 36 (19–58) | 56 (16–111) | 0.44 |
| Nephrotoxicity | 0 | 8 (20) | 0.009 |
| Mortality | |||
| 30-day | 10 (33) | 12 (30) | 0.77 |
| ICU | 14 (47) | 16 (40) | 0.58 |
| In-hospital | 15 (50) | 20 (50) | >0.99 |
TGC, tigecycline; CST, colistin; CPIS, Clinical Pulmonary Infection Score; MV, mechanical ventilation; ICU, intensive care unit.
a Data are presented as the median (interquartile range) or number (percentage) of patients.
b Δ was defined as differences between values on day 7 and baseline of pneumonia diagnosis.
c Patients who died within 30 days of the study period were excluded. TGC group (n = 20) vs. CST group (n = 28).